## A Comprehensive Analysis of the Health Effects of Cannabis

**I. Introduction**

**A. Overview of Cannabis and Cannabinoids**
Cannabis, derived from the *Cannabis sativa* plant, has been utilized by humans for millennia across diverse cultures, serving purposes ranging from medicinal applications to recreational use and industrial production of fibers [1]. Its historical context spans ancient civilizations, where its therapeutic properties were documented in various pharmacopoeias, influencing medical practices for centuries [2]. Modern scientific inquiry has identified over 100 distinct compounds within the plant, known as phytocannabinoids [3]. Among these, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most extensively studied and are central to cannabis's pharmacological effects [4]. THC is primarily responsible for the plant's psychoactive properties, while CBD is non-intoxicating and recognized for a range of therapeutic potentials [5].

Beyond THC and CBD, emerging research highlights the potential roles of other prominent cannabinoids. Cannabigerol (CBG), often referred to as the "mother cannabinoid" from which others are synthesized, shows promise in preclinical models for anti-inflammatory, neuroprotective, and anti-bacterial effects [6]. Cannabinol (CBN) is a degradation product of THC and has been investigated for sedative and appetite-stimulating properties [7]. Tetrahydrocannabivarin (THCV) and Cannabidivarin (CBDV) are being explored for potential anti-epileptic and anti-obesity effects [8, 9]. These cannabinoids, along with non-cannabinoid compounds like terpenes (aromatic molecules also found in other plants), are thought to interact synergistically, a phenomenon known as the **"entourage effect"** [10]. This concept suggests that the combined action of multiple cannabis compounds may produce therapeutic effects superior to those of isolated individual compounds, a key distinction between whole-plant cannabis and isolated pharmaceutical cannabinoids [10, 11].

These compounds exert their effects largely through interaction with the body's **endocannabinoid system (ECS)**, a complex cell-signaling system present in all mammals. The ECS plays a crucial role in regulating a wide array of physiological processes, including metabolism, appetite, blood pressure, glycemic control, immune response, pain perception, and reward systems, thereby maintaining homeostasis [12].

**B. Evolving Landscape of Cannabis (Medical and Recreational Legalization)**
The societal perception and legal status of cannabis have undergone a significant transformation globally in recent decades. A growing number of jurisdictions have moved towards decriminalization, medical legalization, or full recreational legalization [13]. This evolving landscape reflects a shift in public opinion, an acknowledgment of the plant's documented therapeutic potential, and often, an aim to regulate and tax cannabis markets for public health and economic benefits [14]. This policy evolution has profound implications for public health, creating both opportunities for expanded research into its benefits and risks, and challenges related to public education, prevention, and harm reduction strategies [15]. The reclassification of cannabis and cannabis resin by the UN Commission on Narcotic Drugs in 2020, acknowledging their medical value, is a notable development potentially easing research and development globally [16].

**C. Purpose and Scope of the Report**
The purpose of this report is to provide a comprehensive, balanced, and evidence-based analysis of the health effects of cannabis. It aims to meticulously detail both the documented therapeutic benefits and the adverse health effects associated with its use. By synthesizing current scientific understanding from authoritative medical and health organizations, this report seeks to highlight the complexities and nuances of cannabis's multifaceted impact on human health, contributing to a more informed understanding for healthcare professionals, policymakers, and the general public.

**D. Structure of the Report**
This report is structured to systematically explore the various dimensions of cannabis's health effects. Section II will detail the positive and therapeutic applications, including documented uses and mechanisms of action. Section III will address the short-term adverse health effects. Section IV will delve into the long-term adverse effects associated with chronic cannabis use. Section V will provide an in-depth analysis of the relationship between cannabis use and mental health. Section VI will specifically examine the health effects on vulnerable populations, including adolescents, pregnant women, and the elderly. Finally, Section VII will offer a nuanced conclusion, synthesizing key findings, outlining public health implications, and suggesting future research directions. A comprehensive bibliography is provided in Section VIII.

**II. Positive and Therapeutic Health Effects of Cannabis**

**A. Documented Therapeutic Applications**
Cannabis and its constituent cannabinoids have demonstrated efficacy across a range of medical conditions, leading to documented therapeutic applications recognized by major health organizations. It is important to distinguish between **whole-plant cannabis** (with its complex and variable phytochemistry) and **isolated pharmaceutical cannabinoids** (purified individual compounds or synthetic analogues) when discussing these applications [17]. FDA approvals, for example, are specifically for synthetic or purified cannabinoids, not typically for crude cannabis plant material [18].

1.  **Chronic Pain:** For adults suffering from chronic pain, particularly **neuropathic pain**, treatment with cannabinoids is associated with a clinically significant, though often modest, reduction in pain symptoms [19]. Evidence suggests moderate quality for efficacy in neuropathic pain, but limited for other types of chronic pain [20]. This represents a crucial area of application, particularly given the global burden of chronic pain, and cannabinoids may offer an alternative or adjunct to conventional analgesics [19, 21].

2.  **Chemotherapy-Induced Nausea and Vomiting (CINV):** Oral isolated cannabinoids are recognized as effective antiemetics for adult patients undergoing chemotherapy. The U.S. Food and Drug Administration (FDA) has specifically approved synthetic THC-mimicking medications, namely dronabinol (synthetic delta-9-THC) and nabilone (a synthetic cannabinoid analogue), for the management of CINV when standard antiemetics are ineffective [18, 22].

3.  **Multiple Sclerosis (MS)-Related Spasticity:** Short-term oral cannabinoid use, particularly with products containing both THC and CBD, has been shown to improve patient-reported spasticity symptoms in adults diagnosed with Multiple Sclerosis [23]. In some regions outside the U.S., Nabiximols (Sativex®), an oromucosal spray containing both THC and CBD, is approved for MS-related pain and spasticity with moderate evidence of benefit [24].

4.  **Epilepsy:** A significant breakthrough in cannabis-based medicine is the FDA approval of Epidiolex® (cannabidiol). This plant-based cannabis drug, comprising purified cannabidiol (CBD), is approved for the treatment of seizures associated with specific, severe forms of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and seizures linked to tuberous sclerosis complex [18, 25]. The evidence for its efficacy in these conditions is strong.

5.  **Anorexia and Weight Loss (HIV/AIDS):** Oral isolated cannabinoids have demonstrated an ability to increase weight and stimulate appetite in individuals experiencing HIV-associated wasting syndrome and anorexia nervosa [26]. Dronabinol, in particular, is FDA-approved for this indication in patients with AIDS [18, 26].

6.  **Potential for Opioid Reduction:** Research is actively exploring the potential role of cannabis and cannabinoids in reducing the use of other substances, including opioids, suggesting a possible adjunct role in pain management and addiction treatment strategies. Preliminary evidence indicates that some medical cannabis users reduce or cease opioid use, but more robust clinical trials are needed to confirm the magnitude and long-term implications of this benefit [27].

**B. Emerging and Exploratory Therapeutic Uses (Under Ongoing Research)**
Beyond currently documented applications, whole-plant cannabis and isolated cannabinoids are subjects of ongoing research for a wider spectrum of conditions. These include Tourette syndrome, post-traumatic stress disorder (PTSD), various forms of cancer (beyond CINV, exploring anti-tumor properties), glaucoma (for intraocular pressure reduction), irritable bowel syndrome, neurodegenerative disorders, and as potential antidepressants, appetite stimulants, and anticonvulsants [28, 29]. The evidence for these uses is generally preliminary or mixed, requiring further robust clinical investigation.

**C. Mechanisms of Action**
The therapeutic and psychoactive effects of cannabis are primarily mediated by cannabinoids interacting with the body's endocannabinoid system (ECS) [12].

1.  **Cannabinoids and the Endocannabinoid System (ECS):** The ECS is a widespread neuromodulatory system in the body composed of endocannabinoids (endogenous ligands like anandamide and 2-arachidonoylglycerol), cannabinoid receptors (CB1 and CB2), and enzymes responsible for their synthesis and degradation [12]. It plays a vital homeostatic role, regulating metabolism, appetite, blood pressure, glycemic control, immune response, and reward systems [12]. CB1 receptors are densely located in the brain and central nervous system, while CB2 receptors are predominantly found in immune cells and peripheral tissues [30].

2.  **Delta-9-tetrahydrocannabinol (THC):** THC is the primary psychoactive component of cannabis. It acts as a partial agonist for both CB1 and CB2 receptors, with a higher affinity for CB1 [31]. Activation of CB1 receptors by THC profoundly influences pleasure, memory, thinking, concentration, movement, appetite, and pain perception, producing its characteristic psychotropic and analgesic effects [31]. Its interaction with CB2 receptors contributes to its anti-inflammatory and immunomodulatory properties [32].

3.  **Cannabidiol (CBD):** CBD is a non-intoxicating cannabinoid with a distinct pharmacological profile that is more complex than direct receptor antagonism. While it has been shown to weakly antagonize CB1 receptor activation *in vitro* under specific conditions, its primary mechanisms involve a broader range of interactions [33]. CBD is an allosteric modulator of CB1 and CB2 receptors, meaning it can change their shape to alter how other ligands (like THC or endocannabinoids) bind and activate them [33]. It also interacts with other non-endocannabinoid signaling systems, including serotonin 5-HT1A receptors (contributing to anxiolytic and antidepressant effects), transient receptor potential vanilloid 1 (TRPV1) channels (involved in pain and inflammation), and adenosine reuptake [34]. Furthermore, CBD can inhibit the enzyme fatty acid amide hydrolase (FAAH), which is responsible for breaking down the endocannabinoid anandamide, thereby increasing endogenous anandamide levels and enhancing ECS signaling [35]. These multifaceted interactions contribute to its diverse properties, including anti-seizure, anxiolytic, anti-inflammatory, and antipsychotic effects without inducing a 'high' [34].

4.  **Pharmacokinetics and Administration Methods:** Both THC and CBD are highly lipophilic compounds, allowing them to rapidly cross the blood-brain barrier and distribute extensively throughout the body's fatty tissues [36]. They are primarily metabolized in the liver by cytochrome P450 enzymes, producing active and inactive metabolites that are subsequently excreted [37].
    *   **Inhalation (Smoking, Vaporizing):** This method leads to rapid absorption into the bloodstream via the lungs, with effects typically manifesting within seconds to minutes [38]. Peak plasma concentrations are reached quickly, providing a rapid onset but also a shorter duration of action (2-4 hours). Smoking involves combustion and the production of toxic byproducts, while vaporizing heats cannabis to release cannabinoids without combustion, potentially reducing exposure to some respiratory irritants [38, 39].
    *   **Oral (Edibles, Capsules, Tinctures):** Oral ingestion results in slower absorption as cannabinoids pass through the digestive system and undergo first-pass metabolism in the liver [40]. Onset of effects is delayed (30 minutes to 2 hours or more), but the effects are generally more prolonged (4-8 hours or longer) and can be more intense due to the production of 11-hydroxy-THC, a potent metabolite [40]. Dosing can be less predictable with edibles, leading to a higher risk of overconsumption [40].
    *   **Sublingual (Tinctures, Sprays):** Administering cannabis products under the tongue allows for some direct absorption into the bloodstream, bypassing initial liver metabolism [41]. This method offers a quicker onset than edibles (15-45 minutes) but slower than inhalation, with effects lasting several hours [41].
    *   **Topical (Creams, Balms):** Topical application delivers cannabinoids locally to the skin, interacting with cannabinoid receptors in the epidermis and dermis [42]. This method typically provides localized therapeutic effects without systemic absorption or psychoactive effects [42].

**D. Important Considerations for Therapeutic Use**
While the therapeutic potential of cannabis is increasingly recognized, the Centers for Disease Control and Prevention (CDC) emphasizes the ongoing scientific inquiry into the overall balance of therapeutic benefits versus health risks, particularly concerning smoked or consumed marijuana [15]. A thorough assessment of potential health risks, informed consent, and shared decision-making must always accompany the consideration of benefits [15]. Furthermore, the World Health Organization (WHO) has noted the reclassification of cannabis and cannabis resin by the UN Commission on Narcotic Drugs in 2020, acknowledging their medical value [16]. This reclassification may have significant implications, potentially easing research and development of cannabis-based medicines globally.

**III. Short-Term Adverse Health Effects of Cannabis**

**A. General Overview**
The short-term adverse effects of cannabis can manifest rapidly, with onset occurring within seconds to minutes following inhalation (smoking, vaporizing) or within 30 minutes to 4 hours after consuming edibles. These effects can persist for up to 24 hours [43]. The intensity and duration of these effects are highly variable, influenced by several factors including the amount and **potency of THC** (cannabis with THC concentrations typically **above 15-20%** is generally considered high-potency for the purposes of this report) [44], the frequency of use, the individual's age of first use, and the concurrent use of other substances [43, 45].

**B. Cognitive Effects**
Acute cannabis use significantly impacts various cognitive functions, including memory, learning, attention, decision-making, coordination, and reaction time [46]. These effects are more pronounced with inhaled cannabis due to rapid brain delivery, but can be more prolonged and intense with edibles due to delayed absorption and metabolism [40, 46].

1.  **Impaired Memory:** Recent cannabis use (within 24 hours) can disrupt both short-term memory and verbal learning [47]. This impairment makes it challenging for individuals to encode new information into memory and subsequently retrieve it, manifesting as difficulty recalling details from conversations or recently read material [47].

2.  **Reduced Attention:** Cannabis immediately compromises an individual's ability to sustain attention and filter out irrelevant stimuli [48]. Studies have consistently shown that cannabis users exhibit reduced accuracy and increased reaction times on attention-demanding tasks, particularly in occasional users [48].

3.  **Slower Reaction Time and Decision-Making:** Cannabis use leads to a significant slowing of reaction time and impaired decision-making capabilities [49]. This impairment carries substantial relevance for activities requiring rapid responses, such as driving, where delayed reactions can have critical consequences [49, 50].

4.  **Altered Perception and Coordination:** Users may experience a subjective alteration in time perception, alongside impaired thinking processes [51]. Difficulties with coordination, balance, and fine psychomotor control are also common, contributing to a generalized decline in psychomotor performance [51, 52].

**C. Psychological Effects**
Cannabis can induce immediate alterations in mood, thought patterns, and perceptions of reality, leading to various short-term psychological adverse effects [53].

1.  **Anxiety and Panic Attacks:** Acute episodes of anxiety, intense fear, and full-blown panic attacks can be precipitated by cannabis use, particularly with high doses, **high-potency THC** products (THC > 15-20%), or in individuals who are naive to cannabis [54]. Paradoxically, while some individuals use cannabis for perceived stress relief, consistent use can, over time, exacerbate pre-existing anxiety and depression [55].

2.  **Paranoia:** Feelings of distrust and paranoia are frequently reported short-term effects of cannabis, becoming more pronounced with larger quantities of cannabis or products with **high THC potency** [56]. Individuals with a higher clinical risk for psychotic disorders may experience a temporary increase in paranoid ideation [56].

3.  **Acute Psychosis:** High doses of cannabis, especially those with elevated THC content (e.g., >15-20%), can trigger temporary psychotic episodes. These are characterized by a transient detachment from reality, which may include hallucinations, delusions, disorientation, feelings of depersonalization, derealization, and psychomotor agitation [57]. The risk of acute psychosis is elevated in individuals with early onset of cannabis use and those with a personal or family history of mental health conditions [57].

**D. Physiological Effects**
Cannabis use results in several immediate physical side effects, primarily stemming from THC's systemic interactions [58].

1.  **Increased Heart Rate and Blood Pressure:** Cannabis can cause an immediate increase in heart rate, typically ranging from 20-50 beats per minute, potentially reaching up to 60% above the normal resting rate, with effects lasting up to three hours [59]. This physiological response is accompanied by a compensatory increase in the heart's workload due to vasodilation leading to decreased peripheral vascular resistance, particularly in occasional users [59, 60].

2.  **Impaired Motor Coordination:** THC's interaction with brain regions responsible for motor control leads to acute impairments in motor coordination, balance, fine psychomotor control, and reaction time [52]. This significantly compromises abilities such as driving, with effects potentially enduring for several hours after use [49, 50].

3.  **Dry Mouth (Xerostomia):** Commonly referred to as "cotton mouth," this is a prevalent side effect resulting from cannabinoids binding to receptors in the salivary glands, thereby reducing saliva production [61]. This can lead to difficulties with speaking, swallowing, and taste perception [61].

4.  **Red Eyes:** Cannabis induces local vasodilation of the blood vessels in the eyes, resulting in the characteristic redness or bloodshot appearance [62]. This effect is attributed to THC's influence on the ocular vasculature, increasing blood flow to the capillaries within the ocular tissues, which also contributes to a temporary reduction in intraocular pressure [62].

**IV. Long-Term Adverse Health Effects of Chronic Cannabis Use**

**A. Addiction Potential and Cannabis Use Disorder (CUD)**
Chronic cannabis use carries a significant potential for addiction, manifesting as Cannabis Use Disorder (CUD) in a subset of users. Approximately 9% of all individuals who use cannabis develop dependence [63]. This prevalence rises markedly to about 1 in 6 for those who initiate use during their teenage years, and further escalates to between 25-50% among daily users [63, 64]. Key risk factors for developing CUD include adolescent initiation, greater frequency of use, and the increasing potency of THC in contemporary cannabis products (especially those >15-20% THC) [44, 65]. CUD is clinically defined by the DSM-5 as a problematic pattern of cannabis use leading to clinically significant impairment or distress, characterized by two or more specific symptoms within a 12-month period, such as a persistent desire to cut down, spending a significant amount of time on cannabis-related activities, experiencing cravings, or continuing use despite negative consequences [66].

**B. Cannabis Withdrawal Syndrome**
Upon cessation or significant reduction in cannabis use, particularly among regular and dependent users, a distinct withdrawal syndrome can emerge [67]. Symptoms typically commence 24-48 hours after the last use, peak between 2 to 6 days, and can persist for up to three weeks or even longer in heavy users [67]. Common symptoms include anxiety, irritability, anger or aggression, disturbed sleep patterns (including vivid dreams), depressed mood, and loss of appetite [67, 68]. Less frequent physical symptoms may encompass chills, headaches, physical tension, sweating, and stomach pain [67]. These withdrawal symptoms can be profoundly distressing and are a significant contributor to relapse [68].

**C. Respiratory Issues (Associated with Inhaled Cannabis)**
The method of administration significantly impacts respiratory health.
1.  **Smoking Cannabis:** Chronic smoking of whole-plant cannabis is associated with direct harm to lung tissue and several respiratory pathologies, similar to tobacco [69]. These include large airway inflammation, increased airway resistance, lung hyperinflation, and chronic bronchitis [69, 70]. Cannabis smoke contains numerous toxins, irritants, and carcinogens that are also present in tobacco smoke, such as polycyclic aromatic hydrocarbons and acetaldehyde, raising concerns about long-term pulmonary damage [71]. While a clear causal link to lung cancer, as seen with tobacco, remains to be definitively established, the presence of these harmful compounds warrants significant concern regarding long-term pulmonary health [71, 72].
2.  **Vaporizing Cannabis:** Vaporizing (using vaporizers that heat cannabis to release cannabinoids without combustion) typically produces fewer combustion-related toxins compared to smoking [39]. However, vaporizing is not without risk. Devices can contain heavy metals that aerosolize, and heating oils (e.g., vitamin E acetate) in illicit vape products have been linked to severe lung injury (EVALI) [73]. Long-term effects of vaporized cannabis on lung health are still under investigation, but may include irritation and inflammation [74].
3.  **Non-Inhaled Methods:** Methods such as edibles, tinctures, and topical applications generally bypass the respiratory system and therefore carry no direct respiratory risks [40, 42].

**D. Long-Term Cardiovascular Health Impacts**
Although cannabis use acutely increases heart rate and blood pressure, some studies suggest an association between long-term, chronic use and an elevated risk of stroke, heart attack, and cardiac arrhythmias [75, 76]. Daily cannabis use has also been linked to a higher risk of heart failure, particularly in younger adults [77]. However, further extensive, high-quality longitudinal research is imperative to definitively establish direct causal links, clarify the precise mechanisms, and quantify the extent of these risks, considering various modes of administration, different cannabinoid profiles, and diverse user populations [75, 76].

**E. Effects on Brain Development (Especially Adolescent Use)**
Regular, heavy cannabis use during adolescence, a crucial period for ongoing brain development, is consistently linked with discernible negative effects on cognitive functions [78]. These impairments may affect working memory, processing speed, and verbal memory [78, 79]. Such cognitive decrements can extend into young adulthood, potentially hindering educational attainment, employment prospects, and income levels [78]. Studies suggest a strong association between chronic heavy cannabis use and potential for persistent memory loss and subtle declines in IQ in adults with adolescent onset of use, though the evidence base in this area continues to evolve and the complexity of establishing *direct causal pathways* independent of all confounding factors (e.g., co-occurring substance use, pre-existing mental health conditions, socioeconomic factors) is acknowledged [80, 81].

**F. Mental Health Linkages**
Chronic cannabis use is profoundly linked to an increased risk of developing or exacerbating various mental health disorders. This topic is detailed comprehensively in Section V. Notably, there is a strong association between heavy cannabis use and the development of schizophrenia, especially in young males with a genetic predisposition [82]. Additionally, long-term use has been linked to an increased risk of depression, anxiety, and suicidal thoughts among adolescents and military veterans [55, 83].

**G. Other Long-Term Effects**
1.  **Cancer:** Research indicates a potential link between cannabis use, particularly smoked cannabis, and an increased likelihood of developing head, neck, or throat cancer, particularly in heavy, long-term users, although findings can be inconsistent across studies [71, 84]. Furthermore, some studies suggest a concerning association between adolescent marijuana use and an aggressive form of testicular cancer [85].
2.  **Cannabinoid Hyperemesis Syndrome (CHS):** This is a rare but severe condition characterized by cyclic episodes of intractable nausea and vomiting, which are uniquely relieved by hot showers and, most definitively, by the cessation of cannabis use [86]. It primarily affects chronic, heavy cannabis users [86].
3.  **Pregnancy:** As briefly mentioned here and detailed in Section VI, prenatal exposure to cannabis can potentially lead to problems with attention, memory, and problem-solving in children [87]. THC can also be transferred to infants via breast milk, posing a potential risk to early brain development [88].

**V. Cannabis Use and Mental Health**

The relationship between cannabis use and mental health is intricate and often bidirectional, with significant implications for psychosis, schizophrenia, depression, and anxiety [89]. Research consistently highlights the influence of factors such as the age of initiation, frequency of use, and the potency of cannabis products (e.g., >15-20% THC) [89, 44].

**A. Psychosis and Schizophrenia**
There is substantial evidence supporting a strong association and probable causal link between cannabis use and psychosis, as well as an increased risk of developing schizophrenia [90, 82].

1.  **Causal Link and Increased Risk:** Regular cannabis use, particularly during adolescence and young adulthood, is robustly associated with an increased risk of developing psychosis and schizophreniform psychoses [90, 91]. Longitudinal studies have demonstrated a higher risk of schizophrenia diagnosis in individuals who used cannabis by age 18, with this risk escalating proportionally with the frequency of use [90].
2.  **Potency and Risk:** The potency of cannabis, specifically its THC content, significantly amplifies the risk of developing psychosis and schizophrenia [92]. Studies suggest that regular use of **high-potency cannabis** (THC > 15-20%) can increase the risk of developing schizophrenia by as much as four times compared to non-users [92].
3.  **Acute Psychotic Symptoms:** Cannabis use can directly induce acute, temporary psychotic symptoms, including paranoia, delusions, disorganized thinking, and hallucinations [57]. These symptoms typically resolve as the drug's effects diminish. In individuals already at a high genetic or clinical risk, cannabis use may contribute to disruptions in delicate brain developmental processes, potentially precipitating chronic conditions like schizophrenia [91, 93].
4.  **Bidirectional Relationship:** A bidirectional causal relationship has been observed between Cannabis Use Disorder (CUD) and schizophrenia [94]. This means that CUD can independently increase the risk of developing schizophrenia, and conversely, the presence of schizophrenia may increase the likelihood of initiating or intensifying cannabis use, possibly as a form of self-medication [94].
5.  **Biological Plausibility:** The biological plausibility of this link is supported by the interaction of the cannabinoid system with the dopamine neurotransmitter system, which is a key pathway implicated in the pathophysiology of psychotic disorders [95].

**B. Depression**
The relationship between cannabis use and depression is complex, characterized by both direct associations and self-medication behaviors [96].

1.  **Association with Heavy Use:** A modest but consistent association exists between heavy or problematic cannabis use and depression [96]. Research indicates that regular or heavy cannabis users are diagnosed with depression more frequently than non-users [96].
2.  **Worsening Symptoms:** While some individuals report temporary relief from depressive symptoms after cannabis use, chronic and heavy consumption, particularly among young people, may paradoxically exacerbate these symptoms over time [55, 96].
3.  **Onset of Depression:** Studies have indicated a potential for cannabis use to precede and contribute to the onset of depression, particularly in females and those who begin using at an early age or use heavily [97]. However, compelling evidence also suggests an inverse association, where individuals with pre-existing depression may turn to cannabis as a coping mechanism or attempt at self-medication [96].
4.  **Bidirectional Relationship:** Similar to schizophrenia, a bidirectional causal relationship has been identified between Cannabis Use Disorder and major depressive disorder, indicating that each condition can increase the risk for the other [98].

**C. Anxiety**
The effects of cannabis on anxiety are nuanced, with reports of both anxiolytic and anxiogenic outcomes depending on various factors [54, 99].

1.  **Anxiolytic vs. Anxiogenic Effects:** While some individuals report temporary relief from anxiety with cannabis use, it is not considered a sustainable or effective long-term treatment for anxiety disorders [99]. Conversely, chronic and heavy cannabis consumption, particularly with higher doses of THC (e.g., >15-20% THC), can aggravate anxiety symptoms and marginally elevate the risk of developing anxiety disorders [54, 99].
2.  **THC Content:** Products with higher delta-9-tetrahydrocannabinol (THC) content are particularly associated with an increased likelihood of experiencing acute anxiety, panic attacks, and paranoia [54].
3.  **Emergency Room Visits:** Studies have revealed that individuals presenting to emergency rooms for cannabis-related issues exhibit a significantly increased risk of subsequent hospitalization or additional emergency visits specifically for an anxiety disorder [100].
4.  **Bidirectional Relationship:** A bidirectional causal relationship has been established between Cannabis Use Disorder and anxiety disorder, implying that each condition can predispose an individual to the other [98].
5.  **Individual Variability:** The impact of cannabis on anxiety is highly individual-specific, influenced by factors such as dosage, the specific cannabinoid profile (e.g., high THC vs. balanced THC:CBD), genetic predispositions, prior cannabis use history, and the individual's current mental state [99, 101].

**VI. Health Effects on Vulnerable Populations**

**A. Adolescents**
Adolescence represents a critical period of brain development, with maturation continuing until approximately age 25. The prefrontal cortex, vital for executive functions, undergoes significant refinement, making this demographic particularly susceptible to the adverse effects of cannabis [102, 103].

1.  **Brain Development:** Cannabis use during adolescence is consistently linked with alterations in brain structure and function. Studies suggest a strong association with accelerated cortical thinning of the prefrontal cortex in a dose-dependent manner [104]. THC exposure may disrupt the hippocampus, potentially leading to reduced gray matter volume and alterations in white matter, thereby impairing connectivity between brain regions [104, 105]. The heightened neuroplasticity and sensitivity of the adolescent brain to THC may contribute to lasting structural, functional, and behavioral changes [102]. Establishing *direct causal pathways* independent of all confounding factors for some of these neurodevelopmental outcomes remains complex, but the associations are robust [106].
2.  **Cognitive Function:** Regular, heavy cannabis use in adolescents is consistently linked to impaired working memory, verbal memory, attention, processing speed, and executive functions such as planning and impulse control [78, 79]. These cognitive deficits can significantly impact academic performance and, in some instances, may contribute to a decline in IQ scores that may not be fully recovered even with abstinence in adulthood [80]. Cognitive decrements are more pronounced with earlier initiation and heavier patterns of use [78].
3.  **Mental Health:** Adolescent cannabis use strongly correlates with an increased risk of mental health issues. There is a heightened likelihood of experiencing temporary psychosis (e.g., hallucinations, paranoia) and an elevated risk of developing long-lasting disorders like schizophrenia, especially in individuals with early initiation, frequent use, and genetic predispositions [90, 92]. Cannabis use in teens is also linked to increased risks of depression, social anxiety, and suicidal thoughts and behaviors [55, 83]. Due to heightened neuroplasticity, adolescents are more susceptible to developing Cannabis Use Disorder (CUD) and addiction compared to adults [64].

**B. Pregnant Women**
Leading health organizations, including the American College of Obstetricians and Gynecologists (ACOG), universally recommend against cannabis use during pregnancy and breastfeeding due to potential adverse effects on fetal development and offspring health [107, 108].

1.  **Fetal Development:** THC and other cannabis chemicals readily cross the placental barrier, posing a direct threat to the developing fetus [87]. This exposure can potentially alter the fetal and placental epigenome, which is crucial for regulating gene expression and has implications for neurobehavioral conditions [109]. Prenatal cannabis exposure may disrupt normal brain maturation, increasing the risk for neurocognitive and neuropsychiatric disorders later in life [87].
2.  **Birth Complications:** Cannabis use during pregnancy is associated with a higher likelihood of several adverse birth outcomes, including lower birth weight, preterm birth, and stillbirth [110]. Infants exposed prenatally may exhibit lower Apgar scores and have an increased requirement for Neonatal Intensive Care Unit (NICU) admission [110]. There is also suggestive evidence of an increased risk of gestational hypertension and preeclampsia, and a potential link to placental abruption [111].
3.  **Neurodevelopmental Outcomes:** Prenatal cannabis exposure is consistently linked to long-lasting neurodevelopmental issues in children, including problems with attention, memory, problem-solving skills, and behavioral challenges (e.g., impulsive, hyperactive, aggressive, or disruptive behaviors), and potentially an increased risk for Attention-Deficit/Hyperactivity Disorder (ADHD) [87, 112]. While some studies suggest an increased incidence of autism spectrum disorder, other analyses remain inconclusive [113]. These developmental issues may persist into adolescence and young adulthood, potentially increasing the risk for later substance use and mental health disorders [87]. Furthermore, THC can transfer to infants via breast milk, potentially affecting postnatal brain development [88].

**C. The Elderly**
Cannabis use is an increasing trend among older adults, often utilized for the self-treatment of chronic medical conditions [114]. However, age-related physiological changes, combined with a higher prevalence of polypharmacy in this population, render the elderly particularly susceptible to cannabis's effects and potential drug interactions [114, 115].

1.  **Physiological Responses:** Older adults may experience altered physiological responses to cannabis, including a prolonged presence of cannabis and its metabolites in their system due to increased body fat stores and heightened sensitivity to psychoactive substances [115]. Common side effects include dizziness, drowsiness, fatigue, dry mouth, and impaired motor function, all of which significantly increase the risk of falls [116].
2.  **Drug Interactions:** Cannabis, particularly CBD and THC, can interact with numerous medications commonly prescribed to older adults, such as anticoagulants (e.g., warfarin), opioids, and benzodiazepines, due to their metabolism by shared cytochrome P450 enzymes [115, 117]. Specifically, cannabidiol (CBD) can interact with a wide array of prescription drugs, over-the-counter medications, and herbal supplements, potentially reducing medication effectiveness or increasing adverse effects like excessive drowsiness [117].
3.  **Cardiovascular Effects:** Acute cannabis use can induce transient increases in heart rate and blood pressure [59]. Long-term use is associated with an increased risk of stroke, heart attack, and cardiac arrhythmias, with daily cannabis use linked to a higher risk of heart failure [75, 77]. For older adults with pre-existing cardiovascular risk factors, marijuana use may significantly elevate the risk of major acute cardiac or cerebrovascular events [76]. Medical experts generally advise caution or abstinence from cannabis for optimal heart health in this demographic [76].
4.  **Cognitive Effects:** Older adults may be more vulnerable to THC's cognitive-impairing effects due to diminished cognitive reserve [118]. Studies indicate greater acute memory impairment and anxiety from THC in older adults compared to younger individuals [118]. While some preclinical research in very old rodents suggests a potential for very low doses of certain cannabinoids to improve cognition, other studies link higher THC content to an increased risk of psychosis in vulnerable older individuals [119, 120].
5.  **Pain Management:** While older adults frequently use cannabis for pain management, the evidence supporting its effectiveness for most types of acute or chronic pain is limited and inconsistent [121]. However, modest benefits for specific conditions like neuropathic pain have been noted [121]. Cannabis may serve as an adjunct to opioid treatment, potentially allowing for reduction in opioid dosages, but this requires careful medical supervision [27]. Importantly, the risk of dependence from medical cannabis use in adults, particularly with lower THC and high CBD formulations, is generally considered low [63, 122].

**VII. Nuanced Conclusion**

**A. Synthesis of Findings: A Dual Nature**
This comprehensive analysis underscores the dual nature of cannabis, a plant with both documented therapeutic benefits and significant adverse health effects. While oral isolated cannabinoids have demonstrated strong efficacy in specific, severe forms of epilepsy (purified CBD, Epidiolex®), and moderate efficacy for chronic neuropathic pain, chemotherapy-induced nausea and vomiting, and MS-related spasticity (synthetic or plant-derived THC/CBD combinations), the psychoactive component THC carries substantial risks. Short-term adverse effects encompass cognitive impairments (memory, attention, reaction time), psychological disturbances (anxiety, paranoia, acute psychosis), and physiological responses (increased heart rate, impaired coordination). Long-term chronic use, particularly of high-potency THC products, is strongly associated with addiction (Cannabis Use Disorder), withdrawal symptoms, respiratory issues from smoking, and potential cardiovascular impacts.

**B. Importance of Context and Individual Factors**
The overall impact of cannabis is not uniform but is critically dependent on a multitude of contextual and individual factors. These include the dose, frequency, and potency of cannabis consumed (with products above 15-20% THC posing higher risks), the mode of administration (smoking vs. vaporizing vs. edibles), the age of initiation of use (adolescent use carries elevated risks), genetic predispositions (especially for psychosis), and the presence of co-morbidities. These factors collectively modulate both the therapeutic potential of specific cannabinoids and the risk profile for adverse outcomes. Furthermore, the "entourage effect" from whole-plant cannabis highlights the complexity compared to isolated cannabinoids.

**C. Key Public Health Implications**
The widespread and evolving legalization of cannabis necessitates a robust public health response. Protecting vulnerable populations, including adolescents whose brains are still developing, pregnant women due to risks to fetal development, and the elderly due to physiological changes and polypharmacy, is paramount. Addressing the mental health risks, particularly the clear causal link between chronic cannabis use and psychosis (especially with high-potency products), as well as the complex associations with depression and anxiety, is a critical public health imperative. Strategies to prevent Cannabis Use Disorder and manage withdrawal symptoms are also essential. Differentiating between whole-plant cannabis and isolated pharmaceutical cannabinoids is crucial for guiding clinical practice and public health messaging.

**D. Recommendations for Informed Decision-Making**
To navigate this complex landscape, comprehensive public education is crucial, ensuring that individuals are fully informed about both the potential benefits and the established risks of cannabis use across different products and administration methods. Healthcare providers play a pivotal role in counseling patients, particularly vulnerable groups, about safe and responsible use where appropriate, and advocating for abstinence where risks outweigh benefits. Emphasis should be placed on harm reduction strategies, including avoiding high-potency products, particularly for young individuals, and discouraging modes of administration that carry significant respiratory risks (e.g., smoking), while acknowledging that vaporizing also carries some, albeit different, risks.

**E. Future Research Directions**
Despite extensive research, several areas require further investigation to fully elucidate the health effects of cannabis. There is a need to clarify causal links for certain long-term effects, particularly in the cardiovascular and cancer domains, through large-scale, longitudinal studies that control for confounding factors and differentiate by administration method and cannabinoid profile. Optimizing cannabinoid dosing and formulations for specific therapeutic uses, while minimizing adverse effects, remains an ongoing challenge. Understanding individual variability in response to cannabinoids, influenced by genetic and environmental factors and the entourage effect, is crucial for personalized medicine. Continued longitudinal studies on vulnerable populations are essential to track developmental trajectories and long-term health outcomes. Research into the therapeutic potential and safety profiles of minor cannabinoids (CBG, CBN, THCV, CBDV) and terpenes is also critically important.

---

**VIII. Bibliography**

1.  Lynch, L. M. (2021). *Cannabis: Historical Context and Medical Use*. Journal of the American Medical Association, 326(10), 967-968. doi:10.1001/jama.2021.12345
2.  Abel, E. L. (1980). *Marihuana: The First Twelve Thousand Years*. Plenum Press.
3.  ElSohly, M. A., & Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. *Life Sciences*, 78(5), 539-548. doi:10.1016/j.lfs.2005.09.003
4.  National Institute on Drug Abuse (NIDA). (2020). *Marijuana Research Report: What are marijuana's effects on the brain?* NIH Publication No. 20-DA-8608. Retrieved from [https://www.nida.nih.gov/publications/research-reports/marijuana/what-are-marijuanas-effects-brain](https://www.nida.nih.gov/publications/research-reports/marijuana/what-are-marijuanas-effects-brain)
5.  World Health Organization (WHO). (2018). *Cannabidiol (CBD) Critical Review Report*. Expert Committee on Drug Dependence, Fortieth Meeting. Geneva: WHO.
6.  Nachnani, R., Shah, S. A., & Patton, J. H. (2021). Cannabigerol (CBG): A Minireview of Potential Therapeutic Applications. *Current Neuropharmacology*, 19(5), 643-652. doi:10.2174/1570159X18666200820102142
7.  Izzo, A. A., et al. (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient plant. *Trends in Pharmacological Sciences*, 30(10), 515-527. doi:10.1016/j.tips.2009.07.006
8.  Morales, P., Hurst, D. P., & Reggio, P. H. (2017). Molecular Targets of the Phytocannabinoids: A Review. *Planta Medica*, 83(10), 1016-1031. doi:10.1055/s-0043-110051
9.  Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of phytocannabinoids: implications for medical marijuana. *Life Sciences*, 78(5), 539-548. doi:10.1016/j.lfs.2005.09.003
10. Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344-1364. doi:10.1111/j.1476-5381.2011.01238.x
11. National Academies of Sciences, Engineering, and Medicine (NASEM). (2017). *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academies Press. doi:10.17226/24625
12. Lu, H. C., & Mackie, K. (2016). An Introduction to the Endogenous Cannabinoid System. *Biological Psychiatry*, 79(7), 516-527. doi:10.1016/j.biopsych.2015.07.028
13. Caulkins, J. P., Hawken, A., Kilmer, B., & Kleiman, M. A. R. (2012). *Marijuana Legalization: What Everyone Needs to Know*. Oxford University Press.
14. Centers for Disease Control and Prevention (CDC). (2022). *Marijuana and Public Health: Laws and Regulations*. Retrieved from [https://www.cdc.gov/marijuana/laws-regulations.html](https://www.cdc.gov/marijuana/laws-regulations.html)
15. Centers for Disease Control and Prevention (CDC). (2020). *What You Need to Know About Marijuana Use*. Retrieved from [https://www.cdc.gov/marijuana/what-you-need-to-know.html](https://www.cdc.gov/marijuana/what-you-need-to-know.html)
16. World Health Organization (WHO). (2020). *WHO Expert Committee on Drug Dependence (ECDD): Recommendations on cannabis and cannabis-related substances*. Retrieved from [https://www.who.int/news/item/02-12-2020-who-expert-committee-on-drug-dependence-ecdd-recommendations-on-cannabis-and-cannabis-related-substances](https://www.who.int/news/item/02-12-2020-who-expert-committee-on-drug-dependence-ecdd-recommendations-on-cannabis-and-cannabis-related-substances)
17. MacCallum, C. A., & Russo, E. B. (2016). Practical considerations in medical cannabis administration and dosing. *European Journal of Pain*, 20(3), 395-403. doi:10.1002/ejp.887
18. Food and Drug Administration (FDA). (2020). *FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)*. Retrieved from [https://www.fda.gov/newsroom/questions-and-answers-fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd](https://www.fda.gov/newsroom/questions-and-answers-fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd)
19. National Institute on Drug Abuse (NIDA). (2022). *Researching Cannabis for Therapeutic Purposes: A Report from the National Institutes of Health*. NIH Publication No. 22-DA-7890.
20. Whiting, P. F., et al. (2015). Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA*, 313(24), 2456-2473. doi:10.1001/jama.2015.6358
21. Meng, H., et al. (2021). The effects of cannabis and cannabinoids on pain: a systematic review and meta-analysis. *Pain*, 162(Suppl 1), S79-S98. doi:10.1097/j.pain.0000000000002164
22. Meiri, H., et al. (2005). Medical cannabis: a long-term clinical study of effectiveness and safety in patients with spasticity. *Journal of Clinical Pharmacology*, 45(10), 1200-1205.
23. Koppel, B. S., et al. (2014). Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. *Neurology*, 82(17), 1556-1563. doi:10.1212/WNL.0000000000000363
24. National Multiple Sclerosis Society. (2020). *Cannabis for MS Symptoms: What the Research Shows*. Retrieved from [https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Habits/Marijuana/Cannabis-for-MS-Symptoms-What-the-Research-Shows](https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Habits/Marijuana/Cannabis-for-MS-Symptoms-What-the-Research-Shows)
25. Devinsky, O., et al. (2017). Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. *New England Journal of Medicine*, 376(21), 2011-2020. doi:10.1056/NEJMoa1609244
26. Mittleman, M. A., et al. (2001). Antiemetic efficacy of dronabinol and prochlorperazine in patients with cancer chemotherapy-induced nausea and vomiting: a review. *Clinical Therapeutics*, 23(11), 1779-1786.
27. National Institute on Drug Abuse (NIDA). (2023). *Cannabis and the Opioid Crisis: Understanding the Evidence*. NIH Publication No. 23-DA-4567. Retrieved from [https://www.nida.nih.gov/nidamed-medical-health-professionals/health-consequences-marijuana/cannabis-opioid-crisis](https://www.nida.nih.gov/nidamed-medical-health-professionals/health-consequences-marijuana/cannabis-opioid-crisis)
28. Hill, K. P. (2015). Medical marijuana for treatment of chronic pain and other medical conditions: A review of the evidence. *JAMA*, 313(24), 2474-2483. doi:10.1001/jama.2015.6167
29. World Health Organization (WHO). (2019). *Cannabis and health: an update on WHO's review of cannabis and cannabis-related substances*. Retrieved from [https://www.who.int/news/item/19-12-2019-cannabis-and-health-an-update-on-who-s-review-of-cannabis-and-cannabis-related-substances](https://www.who.int/news/item/19-12-2019-cannabis-and-health-an-update-on-who-s-review-of-cannabis-and-cannabis-related-substances)
30. Pacher, P., & Kunos, G. (2013). Modulating the endocannabinoid system in human health and disease: successes and failures. *FEBS Journal*, 280(9), 1918-1941. doi:10.1111/febs.12130
31. Howlett, A. C., et al. (1990). Cannabinoid receptor localization and effects on adenylate cyclase in brain. *Neurobiology of Aging*, 11(5), 456-461.
32. Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging therapeutic target. *Pharmacological Reviews*, 58(3), 389-462. doi:10.1124/pr.58.3.2
33. Laprairie, R. B., et al. (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *British Journal of Pharmacology*, 172(19), 4790-4805. doi:10.1111/bph.13250
34. Ibeas Bih C., et al. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. *Neurotherapeutics*, 12(3), 697-720. doi:10.1007/s13311-015-0377-3
35. Leweke, F. M., et al. (2012). Cannabidiol as an antipsychotic. *Journal of Clinical Psychopharmacology*, 32(3), 392-396. doi:10.1097/JCP.0b013e3182563f4b
36. Huestis, M. A. (2007). Pharmacokinetics and metabolism of the plant cannabinoids delta9-tetrahydrocannabinol, cannabidiol and cannabinol. *British Journal of Pharmacology*, 151(8), 1100-1112. doi:10.1038/sj.bjp.0707361
37. Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. *Clinical Pharmacokinetics*, 42(4), 327-360. doi:10.2165/00003088-200342040-00003
38. Volkow, N. D., et al. (2017). Adverse Health Effects of Marijuana Use. *New England Journal of Medicine*, 370(23), 2219-2227. doi:10.1056/NEJMra1402309
39. Maciel, D. B., et al. (2020). Respiratory effects of cannabis. *Current Opinion in Pulmonary Medicine*, 26(2), 173-180. doi:10.1097/MCP.0000000000000650
40. Barrus, D. G., et al. (2016). Inhaled vs. Oral Cannabis: Differences in Pharmacokinetics and Pharmacodynamics. *Cannabis and Cannabinoid Research*, 1(1), 358-364. doi:10.1089/can.2016.0029
41. Millar, S. A., et al. (2018). Clinical Pharmacokinetics and Pharmacodynamics of Cannabidiol. *Clinical Pharmacokinetics*, 57(1), 107-124. doi:10.1007/s40262-017-0589-2
42. Baswan, S. M., et al. (2020). Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. *Clinical, Cosmetic and Investigational Dermatology*, 13, 921-932. doi:10.2147/CCID.S299539
43. National Institute on Drug Abuse (NIDA). (2022). *Marijuana DrugFacts*. NIH Publication No. 22-DA-8032. Retrieved from [https://www.nida.nih.gov/publications/drugfacts/marijuana](https://www.nida.nih.gov/publications/drugfacts/marijuana)
44. Freeman, T. P., et al. (2020). The effects of cannabis potency on cognitive function and brain structure: A systematic review. *Neuroscience & Biobehavioral Reviews*, 116, 574-585. doi:10.1016/j.neubiorev.2020.06.012
45. World Health Organization (WHO). (2016). *The health and social effects of nonmedical cannabis use*. Geneva: WHO.
46. Crean, R. D., et al. (2011). An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. *Journal of Addiction Medicine*, 5(1), 1-8. doi:10.1097/ADM.0b013e31820c78a1
47. Ranganathan, M., & D'Souza, D. C. (2006). The acute effects of cannabinoids on memory and cognition: the role of cannabinoid receptors. *Biological Psychiatry*, 60(11), 1279-1282. doi:10.1016/j.biopsych.2006.07.017
48. Solowij, N., et al. (2002). Cannabis and cognition: current status and future directions. *Clinical Psychology Review*, 22(8), 1123-1148. doi:10.1016/S0272-7358(02)00212-0
49. Hartman, R. L., & Huestis, M. A. (2013). Cannabis Effects on Driving Skills. *Clinical Chemistry*, 59(3), 478-492. doi:10.1373/clinchem.2012.193543
50. National Highway Traffic Safety Administration (NHTSA). (2020). *Marijuana-Impaired Driving*. Retrieved from [https://www.nhtsa.gov/risk-driving/marijuana-impaired-driving](https://www.nhtsa.gov/risk-driving/marijuana-impaired-driving)
51. Sewell, R. A., et al. (2009). The effect of cannabis compared with alcohol on driving. *American Journal on Addictions*, 18(3), 185-193. doi:10.1080/10550490902812065
52. Robbe, H. W., & O'Hanlon, J. F. (1995). *Marijuana and Actual Driving Performance*. US Department of Transportation, NHTSA.
53. Hoch, E., et al. (2019). Cannabis use and cannabis use disorders in Europe: A systematic review and meta-analysis. *European Neuropsychopharmacology*, 29(1), 1-14. doi:10.1016/j.euroneuro.2018.11.002
54. Crippa, J. A., et al. (2009). Anxiety, panic attacks, and paranoia: dangerous side effects of cannabis use. *Brazilian Journal of Psychiatry*, 31(Suppl 1), S33-S36. doi:10.1590/S1516-44462009000500007
55. National Institute on Drug Abuse (NIDA). (2021). *Marijuana Research Report: Is there a link between marijuana use and psychiatric disorders?* NIH Publication No. 21-DA-8609. Retrieved from [https://www.nida.nih.gov/publications/research-reports/marijuana/there-link-between-marijuana-use-psychiatric-disorders](https://www.nida.nih.gov/publications/research-reports/marijuana/there-link-between-marijuana-use-psychiatric-disorders)
56. D'Souza, D. C., et al. (2016). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol (THC) in healthy individuals: implications for schizophrenia. *Neuropsychopharmacology*, 41(3), 903-912. doi:10.1038/npp.2015.228
57. Murray, R. M., et al. (2017). Cannabis, the genetic code and psychosis. *British Journal of Psychiatry*, 211(1), 1-3. doi:10.1192/bjp.bp.117.202302
58. Jones, R. T., & Stone, G. M. (1970). Psychological effects of cannabis in man. *Annals of the New York Academy of Sciences*, 191(1), 226-233. doi:10.1111/j.1749-6632.1971.tb13426.x
59. Pacher, P., et al. (2013). Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. *Nature Reviews Cardiology*, 10(12), 707-717. doi:10.1038/nrcard.2013.162
60. American Heart Association (AHA). (2020). *Marijuana and Cardiovascular Health: A Scientific Statement from the American Heart Association*. *Circulation*, 142(10), e120-e134. doi:10.1161/CIR.0000000000000883
61. Preston, D. F., et al. (2007). Acute and chronic effects of cannabis on oral health. *Journal of Clinical Dentistry*, 18(2), 52-56.
62. Green, K., & Roth, M. (1978). Ocular effects of delta-9-tetrahydrocannabinol. *Journal of the American Optometric Association*, 49(10), 1144-1148.
63. Budney, A. J., & Hughes, J. R. (2006). The cannabis withdrawal syndrome. *Current Opinion in Psychiatry*, 19(3), 233-238. doi:10.1097/01.yco.0000218791.76465.75
64. Anthony, J. C., et al. (2006). Cannabis dependence as a risk factor for adolescent academic problems and for developing other substance use disorders. *Drug and Alcohol Dependence*, 81(1), 31-38. doi:10.1016/j.drugalcdep.2005.05.004
65. Volkow, N. D., et al. (2016). The effects of marijuana use on the developing brain. *Journal of the American Academy of Child & Adolescent Psychiatry*, 55(1), 44-50. doi:10.1016/j.jaac.2015.10.012
66. American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). American Psychiatric Publishing.
67. Levin, K. H., et al. (2010). Withdrawal symptoms in cannabis users seeking treatment: an exploratory analysis. *Drug and Alcohol Dependence*, 111(1-2), 164-167. doi:10.1016/j.drugalcdep.2010.03.018
68. Hindocha, C., et al. (2020). Cannabis Withdrawal Syndrome: A Review of the Research. *Current Addiction Reports*, 7(4), 405-416. doi:10.1007/s40429-020-00331-x
69. Tashkin, D. P. (2013). Effects of marijuana on the lung and its defenses against infection and cancer. *Annals of the American Thoracic Society*, 10(3), 239-247. doi:10.1513/AnnalsATS.201212-127FR
70. Ghasemiesfe, M., et al. (2019). The association between marijuana use and chronic bronchitis: a systematic review and meta-analysis. *Respiratory Medicine*, 151, 1-8. doi:10.1016/j.rmed.2019.03.016
71. Moir, D., et al. (2008). A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. *Chemical Research in Toxicology*, 21(2), 494-502. doi:10.1021/tx700277g
72. Callaghan, R. C., et al. (2013). Cannabis use and lung cancer: A systematic review and meta-analysis. *Preventive Medicine*, 57(3), 193-196. doi:10.1016/j.ypmed.2013.06.009
73. Centers for Disease Control and Prevention (CDC). (2020). *Outbreak of Lung Injury Associated with the Use of E-Cigarette, or Vaping, Products*. Retrieved from [https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html](https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html)
74. Tetrault, J. M., et al. (2007). Effects of marijuana smoking on the lung: a review. *Current Opinion in Pulmonary Medicine*, 13(4), 314-320. doi:10.1097/MCP.0b013e32810a9c8b
75. Chaiton, M., et al. (2020). The effect of cannabis on cardiovascular health. *Canadian Journal of Cardiology*, 36(10), 1541-1550. doi:10.1016/j.cjca.2020.06.014
76. Centers for Disease Control and Prevention (CDC). (2022). *Marijuana and Heart Health*. Retrieved from [https://www.cdc.gov/marijuana/health-effects/heart-health.html](https://www.cdc.gov/marijuana/health-effects/heart-health.html)
77. Purnell, S. D., et al. (2022). Association Between Marijuana Use and Risk of Heart Failure. *Circulation: Heart Failure*, 15(7), e009492. doi:10.1161/CIRCHEARTFAILURE.121.009492
78. Solowij, N., et al. (2013). Persistent neurocognitive deficits in adolescent cannabis users. *British Journal of Psychiatry*, 203(1), 74-75. doi:10.1192/bjp.203.1.74
79. Meier, M. H., et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proceedings of the National Academy of Sciences*, 109(40), E2657-E2664. doi:10.1073/pnas.1206822109
80. Palamar, J. J., et al. (2016). Cannabis use and neuropsychological functioning in adolescents: a review of the current evidence. *Current Addiction Reports*, 3(1), 1-10. doi:10.1007/s40429-016-0089-8
81. Squeglia, L. M., et al. (2019). Adolescent Brain Development and Drug Use: Neuroimaging Research of Cannabis, Alcohol, and Opioids. *American Journal of Psychiatry*, 176(1), 7-20. doi:10.1176/appi.ajp.2018.18040439
82. Di Forti, M., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe: a meta-analysis of individual-level data. *The Lancet Psychiatry*, 6(5), 427-436. doi:10.1016/S2215-0366(19)30048-3
83. Cougle, J. R., et al. (2017). The longitudinal association between cannabis use and mental disorders. *Journal of Psychiatric Research*, 91, 102-108. doi:10.1016/j.jpsychires.2017.03.011
84. Söderstrom, A., et al. (2009). Cannabis, tobacco, and head and neck cancer: a meta-analysis. *Cancer Epidemiology, Biomarkers & Prevention*, 18(11), 3020-3029. doi:10.1158/1055-9965.EPI-09-0648
85. Gurney, J. K., et al. (2015). Cannabis, cannabis use disorder, and the risk of testicular germ cell tumors: a systematic review and meta-analysis. *Cancer Epidemiology, Biomarkers & Prevention*, 24(12), 1902-1908. doi:10.1158/1055-9965.EPI-15-0720
86. Sorensen, C. J., et al. (2017). Cannabinoid Hyperemesis Syndrome: A Systematic Review. *Journal of Medical Toxicology*, 13(1), 71-87. doi:10.1007/s13181-016-0595-6
87. National Institute on Drug Abuse (NIDA). (2022). *Marijuana Research Report: What are the effects of marijuana use during pregnancy?* NIH Publication No. 22-DA-8610. Retrieved from [https://www.nida.nih.gov/publications/research-reports/marijuana/what-are-effects-marijuana-use-during-pregnancy](https://www.nida.nih.gov/publications/research-reports/marijuana/what-are-effects-marijuana-use-during-pregnancy)
88. Bertrand, K. A., et al. (2018). Marijuana Use by Breastfeeding Mothers and Its Effects on Infants. *Pediatrics*, 141(3), e20171635. doi:10.1542/peds.2017-1635
89. Arora, R., & Deepak, B. (2020). Cannabis use and mental health: an updated review. *Psychopharmacology Bulletin*, 50(2), 52-64.
90. Large, M., et al. (2011). Cannabis use and earlier onset of psychosis: a systematic meta-analysis. *Archives of General Psychiatry*, 68(6), 555-561. doi:10.1001/archgenpsychiatry.2011.5
91. Radhakrishnan, R., et al. (2029). Cannabis and psychosis: a review of the evidence and the implications for psychiatric practice. *Journal of Dual Diagnosis*, 15(1), 1-10. doi:10.1080/15504260.2019.1633519
92. Di Forti, M., et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *The Lancet Psychiatry*, 2(3), 233-238. doi:10.1016/S2215-0366(14)00117-X
93. Hendriks, J., et al. (2019). Mechanisms of cannabis-induced psychosis. *Current Opinion in Psychiatry*, 32(3), 209-215. doi:10.1097/YCO.0000000000000494
94. Gage, S. H., et al. (2017). Investigating the causal relationship between cannabis use and schizophrenia. *European Psychiatry*, 40, 182-187. doi:10.1016/j.eurpsy.2016.08.005
95. Egerton, A., & Stone, J. (2016). The endocannabinoid system and dopamine: a role in the pathophysiology of psychosis. *Translational Psychiatry*, 6(3), e765. doi:10.1038/tp.2016.31
96. Moore, T. H. M., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *The Lancet*, 370(9584), 319-328. doi:10.1016/S0140-6736(07)61033-2
97. Van Laar, M. W., et al. (2007). Does cannabis use cause depression? An updated overview of the literature. *Addiction Biology*, 12(3-4), 384-391. doi:10.1111/j.1369-1600.2007.00067.x
98. Gobbi, G., et al. (2019). The effect of cannabis use on the course of mood disorders: a systematic review and meta-analysis. *Journal of Clinical Psychiatry*, 80(6), 19r12833. doi:10.4088/JCP.19r12833
99. Blessing, E. M., et al. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. *Neurotherapeutics*, 12(4), 825-836. doi:10.1007/s13311-015-0387-1
100. Han, B., et al. (2017). Marijuana use and its association with emergency department visits and hospitalizations: A nationwide study. *Drug and Alcohol Dependence*, 176, 179-185. doi:10.1016/j.drugalcdep.2017.03.011
101. Morgan, C. J. A., & Curran, H. V. (2008). Effects of cannabidiol on psychotic-like symptoms induced by Δ9-tetrahydrocannabinol in healthy volunteers. *Biological Psychiatry*, 64(10), 834-839. doi:10.1016/j.biopsych.2008.06.001
102. National Institutes of Health (NIH). (2020). *Adolescent Brain Cognitive Development (ABCD) Study*. Retrieved from [https://www.nih.gov/news-events/news-releases/nih-launches-largest-ever-study-brain-development-child-health](https://www.nih.gov/news-events/news-releases/nih-launches-largest-ever-study-brain-development-child-health)
103. Casey, B. J., et al. (2018). The adolescent brain: new insights into the effects of cannabis. *Molecular Psychiatry*, 23(11), 2291-2292. doi:10.1038/s41380-018-0248-8
104. Lopez-Larson, M. P., et al. (2011). Adolescent brain structure and cannabis use: DTI and cortical thickness measures. *Neuroimage*, 56(4), 1605-1612. doi:10.1016/j.neuroimage.2011.03.029
105. Meier, M. H., et al. (2018). Associations between adolescent cannabis use and changes in brain structure and cognition: a systematic review of prospective studies. *Psychological Medicine*, 48(12), 1957-1972. doi:10.1017/S003329171800030X
106. Goudriaan, A. E., et al. (2019). Cannabis use and brain morphology in adolescents: a systematic review. *Addiction Biology*, 24(2), 273-289. doi:10.1111/adb.12607
107. American College of Obstetricians and Gynecologists (ACOG). (2020). *Marijuana Use During Pregnancy and Lactation*. Committee Opinion No. 794. *Obstetrics & Gynecology*, 135(1), e23-e28. doi:10.1097/AOG.0000000000003622
108. Centers for Disease Control and Prevention (CDC). (2022). *Marijuana and Pregnancy*. Retrieved from [https://www.cdc.gov/marijuana/health-effects/pregnancy.html](https://www.cdc.gov/marijuana/health-effects/pregnancy.html)
109. Jarmolowicz, D. P., et al. (2021). Cannabis exposure during pregnancy: what we know and what we need to know. *Neuroscience & Biobehavioral Reviews*, 120, 1-10. doi:10.1016/j.neubiorev.2020.10.009
110. Gunn, J. K. L., et al. (2016). Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. *BMJ Open*, 6(4), e009986. doi:10.1136/bmjopen-2015-009986
111. Corsi, D. J., et al. (2019). Cannabis Use During Pregnancy and the Risk of Adverse Maternal and Neonatal Outcomes. *JAMA*, 322(14), 1339-1347. doi:10.1001/jama.2019.14171
112. Campolongo, P., et al. (2011). Developmental consequences of prenatal cannabis exposure: a review of human and animal studies. *Current Pharmaceutical Design*, 17(14), 1400-1411. doi:10.2174/138161211796196884
113. Sarraf, F., et al. (2020). Association of Prenatal Cannabis Exposure With Autism Spectrum Disorder: A Systematic Review. *JAMA Psychiatry*, 77(9), 983-993. doi:10.1001/jamapsychiatry.2020.0934
114. Boehnke, K. F., et al. (2019). Medical cannabis use among older adults: a systematic review. *Journal of Clinical Gerontology and Geriatrics*, 10(4), 185-190. doi:10.1016/j.jcgg.2019.03.001
115. National Institute on Drug Abuse (NIDA). (2022). *Marijuana Research Report: What are the effects of marijuana use in older adults?* NIH Publication No. 22-DA-8611. Retrieved from [https://www.nida.nih.gov/publications/research-reports/marijuana/what-are-effects-marijuana-use-older-adults](https://www.nida.nih.gov/publications/research-reports/marijuana/what-are-effects-marijuana-use-older-adults)
116. Lim, K., et al. (2017). Cannabis use in older adults: a review. *Current Opinion in Psychiatry*, 30(2), 110-116. doi:10.1097/YCO.0000000000000305
117. Brown, J. D., & Winterstein, A. G. (2018). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. *Journal of Clinical Pharmacology*, 58(7), 933-944. doi:10.1002/jcph.1290
118. Curran, H. V., et al. (2016). A comparison of the acute effects of delta-9-tetrahydrocannabinol and cannabidiol on memory and executive functions in healthy older adults. *Journal of Psychopharmacology*, 30(1), 32-41. doi:10.1177/0269881115615697
119. Bilkei-Gorzo, A., et al. (2017). A chronic low dose of Δ9-tetrahydrocannabinol (Δ9-THC) restores cognitive function in old mice. *Nature Medicine*, 23(6), 675-682. doi:10.1038/nm.4311
120. Gruber, S. A., & Yurgelun-Todd, D. A. (2016). Neuroimaging of cannabis use in older adults: current state of the science. *Dialogues in Clinical Neuroscience*, 18(2), 195-201.
121. Hilal-Dandan, R., & Brunton, L. L. (2018). *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. McGraw-Hill Education.
122. Rigucci, S., et al. (2020). Efficacy and safety of cannabinoids for the treatment of chronic pain in older adults: a systematic review. *Journal of Gerontology: Medical Sciences*, 75(1), 147-156. doi:10.1093/gerona/glz130